DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00645788 (ClinicalTrials.gov)	May 2008	26/3/2008	Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis	Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Inhaled Ciprofloxacin Compared to Placebo in Subjects With Cystic Fibrosis	Cystic Fibrosis	Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939);Drug: Placebo	Bayer	Novartis	Completed	12 Years	N/A	All	288	Phase 2	United States;Australia;Canada;Denmark;Germany;Israel;Norway;Sweden;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00645788
(ClinicalTrials.gov)

May 2008

26/3/2008

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Inhaled Ciprofloxacin Compared to Placebo in Subjects With Cystic Fibrosis

Cystic Fibrosis

Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939);Drug: Placebo

Bayer

Novartis

Completed

12 Years

N/A

All

288

Phase 2

United States;Australia;Canada;Denmark;Germany;Israel;Norway;Sweden;United Kingdom